Table 1.
MPN-COVID clinical and laboratory characteristics in survivors and non-survivors.
| N non-missing | TOTAL | Survivors | Non-survivors | p value | |
|---|---|---|---|---|---|
| N = 175 | N = 125 | N = 50 | |||
| Sex (female/male), n (%) | 175 | 73/102 (41.7%/58.3%) | 58/67 (46.4%/53.6%) | 15/35 (30.0%/70.0%) | 0.062 |
| Age, years, median (IQR) | 174 | 71.0 (60.0–79.9) | 69.5 (57.6–78.9) | 74.1 (69.6–82.1) | 0.001 |
| <60 years, n (%) | 42 (24.1%) | 40 (32.0%) | 2 (4.1%) | <0.001 | |
| 60–70 years, n (%) | 37 (21.3%) | 24 (19.2%) | 13 (26.5%) | ||
| >70 years, n (%) | 95 (54.6%) | 61 (48.8%) | 34 (69.4%) | ||
| MPN type, n (%) | 175 | ||||
| Essential thrombocythemia | 51 (29.1%) | 38 (30.4%) | 13 (26.0%) | 0.56 | |
| Polycythemia vera | 46 (26.3%) | 37 (29.6%) | 9 (18.0%) | 0.12 | |
| Myelofibrosis | 60 (34.3%) | 36 (28.8%) | 24 (48.0%) | 0.016 | |
| Prefibrotic primary myelofibrosis | 18 (10.3%) | 14 (11.2%) | 4 (8.0%) | 0.53 | |
| Time from MPN to COVID-19 diagnosis, years, median (IQR) | 174 | 6.0 (3.1–11.0) | 6.0 (3.1–10.4) | 5.8 (3.2–11.5) | 0.81 |
| JAK2V617F, n (%) | 170 | 123 (72.4%) | 90 (73.2%) | 33 (70.2%) | 0.70 |
| CALR, n (%) | 95 | 27 (28.4%) | 20 (30.3%) | 7 (24.1%) | 0.54 |
| MPL, n (%) | 90 | 5 (5.6%) | 2 (3.2%) | 3 (10.7%) | 0.15 |
| Palpable splenomegaly, n (%) | 153 | 41 (26.8%) | 28 (26.2%) | 13 (28.3%) | 0.92 |
| MPN drugs, n (%) | |||||
| Hydroxyurea | 175 | 79 (45.1%) | 60 (48.0%) | 19 (38.0%) | 0.23 |
| Discontinued after COVID-19 onset | 52 | 9 (17.3%) | 7 (21.2%) | 2 (10.5%) | 0.33 |
| Ruxolitinib | 175 | 45 (25.7%) | 25 (20.0%) | 20 (40.0%) | 0.006 |
| Discontinued after COVID-19 onset | 45 | 11 (24.4%) | 2 (8.0%) | 9 (45.0%) | 0.004 |
| Interferon | 175 | 4 (2.3%) | 4 (3.2%) | 0 (0.0%) | 0.20 |
| Anagrelide | 175 | 8 (4.6%) | 5 (4.0%) | 3 (6.0%) | 0.57 |
| Other | 175 | 5 (2.3%) | 4 (3.2%) | 1 (2.0%) | 0.67 |
| Comorbidities, n (%) | |||||
| Cerebrovascular disease | 174 | 23 (13.2%) | 17 (13.7%) | 6 (12.0%) | 0.76 |
| Chronic dialysis/Kidney disease | 174 | 19 (10.9%) | 9 (7.3%) | 10 (20.0%) | 0.015 |
| Chronic heart failure | 173 | 25 (14.5%) | 13 (10.6%) | 12 (24.0%) | 0.023 |
| Chronic obstructive pulmonary disease | 174 | 25 (14.4%) | 16 (12.9%) | 9 (18.0%) | 0.39 |
| Current/former tobacco smoker | 152 | 35 (23.0%) | 22 (20.2%) | 13 (30.2%) | 0.19 |
| Hyperlipidemia | 168 | 47 (28.0%) | 36 (29.8%) | 11 (23.4%) | 0.41 |
| Hypertension | 171 | 104 (60.8%) | 70 (57.9%) | 34 (68.0%) | 0.22 |
| Diabetes mellitus | 172 | 23 (13.4%) | 12 (9.8%) | 11 (22.4%) | 0.027 |
| Blood values at COVID-19 diagnosis, median (IQR) | |||||
| Hemoglobin, g/dL | 145 | 12.4 (10.0–13.6) | 12.6 (10.4–13.5) | 11.7 (9.5–13.9) | 0.37 |
| White blood cells, ×109/L | 145 | 6.5 (4.6–10.1) | 6.4 (4.5–9.2) | 7.1 (5.0–11.7) | 0.14 |
| Lymphocytes, ×109/L | 130 | 0.9 (0.6–1.6) | 0.9 (0. 6–1.6) | 0.7 (0.6–1.1) | 0.098 |
| Neutrophils/lymphocytes ratio | 125 | 5.4 (3.4–8.9) | 5.0 (3.3–8.6) | 7.3 (4.5–9.9) | 0.029 |
| Platelets, ×109/L | 143 | 252.0 (152.0–394.0) | 260.5 (170.5–437.5) | 245.0 (121.0–338.0) | 0.14 |
| O2 saturation, %, median (IQR) | 114 | 93.0 (88.0–96.0) | 94.0 (91.0–96.0) | 90.0 (88.0–93.0) | <0.001 |
| Disposition, n (%) | 175 | <0.001 | |||
| Home | 40 (22.9%) | 38 (30.4%) | 2 (4.0%) | ||
| Regular ward | 116 (66.3%) | 80 (64.0%) | 36 (72.0%) | ||
| Intensive care unit | 19 (10.9%) | 7 (5.6%) | 12 (24.0%) | ||
| Main symptoms, n (%) | |||||
| Fever | 175 | 140 (80.0%) | 99 (79.2%) | 41 (82.0%) | 0.68 |
| Dispnea | 175 | 97 (55.4%) | 66 (52.8%) | 31 (62.0%) | 0.27 |
| Gastrointestinal | 175 | 22 (12.6%) | 12 (9.6%) | 10 (20.0%) | 0.061 |
| Need of respiratory support, n (%) | 174 | 103 (59.2%) | 59 (47.2%) | 44 (89.8%) | <0.001 |
| None | 71 (40.8%) | 66 (52.8%) | 5 (10.2%) | <0.001 | |
| Non-invasive | 83 (47.7%) | 53 (42.4%) | 30 (61.2%) | ||
| Invasive | 20 (11.5%) | 6 (4.8%) | 14 (28.6%) | ||
| COVID-19 drugs, n (%) | |||||
| Steroid | 162 | 45 (27.8%) | 28 (23.7%) | 17 (38.6%) | 0.060 |
| Antibiotic | 162 | 114 (70.4%) | 77 (65.8%) | 37 (82.2%) | 0.040 |
| Hydroxychloroquine | 166 | 100 (60.2%) | 73 (59.8%) | 27 (61.4%) | 0.86 |
| Antiviral | 166 | 57 (34.3%) | 43 (35.8%) | 14 (30.4%) | 0.51 |
| Lopinavir/Ritonavir | 53 | 46 (86.8%) | 33 (82.5%) | 13 (100.0%) | 0.17 |
| Other | 53 | 7 (13.2%) | 7 (17.5%) | 0 (0.0%) | |
| Experimental | 170 | 19 (11.2%) | 11 (8.9%) | 8 (17.0%) | 0.13 |
| Tocilizumab | 19 | 15 (78.9%) | 7 (63.6%) | 8 (100.0%) | 0.39 |
| Ruxolitinib | 19 | 2 (10.5%) | 2 (18.2%) | 0 (0.0%) | |
| Other | 19 | 2 (10.5%) | 2 (18.2%) | 0 (0.0%) | |
| Antithrombotic | 166 | 93 (56.0%) | 70 (57.9%) | 23 (51.1%) | 0.44 |
| Direct oral anticoagulants | 92 | 2 (2.2%) | 2 (2.9%) | 0 (0.0%) | 1.00 |
| Low molecular weight heparin | 92 | 89 (96.7%) | 66 (95.7%) | 23 (100.0%) | |
| Warfarin | 92 | 1 (1.1%) | 1 (1.4%) | 0 (0.0%) | |
Univariate analysis.
MPN myeloproliferative neoplasms.